After the FDA approved Valeant's Siliq, Wells Fargo says that the approval was already included in consensus models, while the label is worse than expected. Specifically, the label unexpectedly says that the drug is intended for patients who have not responded to or have stopped responding to other therapies, It includes a boxed warning about suicide and requires that prescribers be certified and counsel patients about suicide. Wells says that doctors are likely to be "very worried about potential liability" given the label's strictness on the suicide issue.It recommends selling Valeant stock.